The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS: National Grid backs outlook after strong full-year results

Thu, 19th May 2022 11:00

(Alliance News) - National Grid PLC on Thursday backed its five-year outlook on a strong financial 2022 performance due to smaller hit from Covid-19, and lifted its payout to shareholders.

Further, the London-based power transmission and distribution firm reported progress in its sale of Narragansett Electric Co to PPL Corp.

It recorded a pretax profit of GBP3.44 billion for the year ended March 31, more than doubled compared to GBP1.66 billion generated the year before.

This was on revenue growth of 35% to GBP18.45 billion from GBP13.67 billion.

The company attributed its performance to a "lower adverse impact" from Covid-19 compared to financial 2021, higher UK Electricity Transmission net revenue and the first year of operation of IFA2 and the North Sea Link. IFA2 is a subsea electrical interconnector, running beneath the English Channel between France and the UK. The North Sea Link is a high-voltage direct current submarine power cable between Norway and the UK.

National Grid proposed a final dividend of 33.76 pence for financial 2022, an increase of 5.0% from 32.16p a year earlier. This brought its full-year dividend to 50.97p, up 3.7% from 49.16p, in line with its policy.

National Grid backed its outlook for the five-year period from financial 2021 to financial 2026.

Looking ahead, the company also continues to expect the sale of its Rhode Island utility business, Narragansett Electric Co, to be completed in the first quarter of this financial year. It said it has obtained regulatory clearances for the sale and is currently awaiting the conclusion of the legal process.

The sale of a 60% stake in National Grid Gas is still anticipated to be completed in the third quarter of this financial year.

In March, the FTSE 100 company announced the sale of Narragansett Electric Co to PPL for USD3.8 billion. In the same month, it agreed to sell a 60% interest in its gas transmission and metering business in the UK to a consortium of "long-term infrastructure investors" for GBP2.2 billion in cash. Both sales are part of its strategy to shift its portfolio focus towards electricity and away from gas, following last year's acquisition of power-distribution company Western Power Distribution for GBP7.8 billion.

For financial 2023, National Grid expects earnings to be "broadly flat" on financial 2022, assuming an exchange rate of GBP1 equalling USD1.30.

"Our purchase of WPD has pivoted our business to a much greater focus on electricity infrastructure, putting us at the heart of delivering the energy transition. We've invested a record GBP6.7 billion in critical energy infrastructure, part of our five-year GBP30 billion to GBP35 billion investment programme. Over 70% of our five-year investment is aligned to EU taxonomy principles making us one of the FTSE's largest investors in the delivery of net-zero," Chief Executive John Pettigrew said.

Separately, National Grid announced that Iain Mackay, chief financial officer at FTSE 100 listed pharmaceutical firm GSK PLC, is joining its board as a non-executive director. Prior to joining National Grid and GSK, Iain was group finance director at HSBC Holdings PLC.

"As part of our ongoing board refreshment process, it will be invaluable to have Iain in the National Grid boardroom. His breadth of experience across continents, industries and business functions will bring additional depth to our deliberations in what has emerged as a fast-moving environment," Chair Paula Rosput Reynolds said.

National Grid shares were trading 2.2% lower at 1,218.50 pence each in London on Thursday morning.

By Abby Amoakuh; abbyamoakuh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.